Untitled

Kishikawa, Hiroshi; Nishida, Jiro; Nakano, Masaru; Hirano, Erika; Morishita, Tetsuo; Ishii, Hiromasa

doi:10.1023/a:1024179730817

Cited by 8 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intestinal microbiome imbalance, dysbiosis, can promote the suppression of hematopoiesis. In inflammatory bowel diseases (IBD), which are characterized by commensal intestinal bacteria imbalance, a condition of non-drug dependent aplastic anemia can occur 11 , 12 . Table 1 reports the correlation between microbiota and some of the most frequent onco-hematologic pathologies, specifying the microbial populations involved or suspected and their mechanisms 13 .…”

Section: Introductionmentioning

confidence: 99%

Microbiota and Hematological Diseases

D’Angelo¹

2022

IJHOSCR

View full text Add to dashboard Cite

The microbiota is directly involved in the host metabolic process, as well as in immune response modulation and recruitment of different cells typology in the inflammatory site. Human microbiota modification (dysbiosis) is a condition which could be correlated with various pathologies. The short-chain fatty acids produced by the metabolic process have an important role as immune mediators. In hematology field, dysbiosis can represent a predisposing condition for triggering and/or conditioning both non-neoplastic (iron deficiency anemia, thrombosis, thrombocytosis or thrombocytopenia) and neoplastic disorders (lymphomas, leukemias, myeloma). Dysbiosis may also interfere on therapy efficacy (iron supplementation, chemotherapy, immunotherapy, and hematopoietic stem cell transplantation), impacting on patient's outcome.

show abstract

Section: Introductionmentioning

confidence: 99%